Somatically acquired epigenetic changes are present in many cancers. Epigenetic regulation is maintained via post-translational modifications of core histones. Here, we describe inactivating somatic mutations in the histone lysine demethylase gene UTX, pointing to histone H3 lysine methylation deregulation in multiple tumor types. UTX reintroduction into cancer cells with inactivating UTX mutations resulted in slowing of proliferation and marked transcriptional changes. These data identify UTX as a new human cancer gene.
In the nuclei of eukaryotic cells, DNA is packed into chromatin. The basic constituent of chromatin, the nucleosome, is comprised of 147 bp of DNA wound around an octamer of core histone proteins. Post-translational modifications of the N-terminal tails of these core histone proteins, including methylation, acetylation, ubiquitylation and phosphorylation 1 , modulate chromatin configuration and mediate access to nuclear protein factors, resulting in changes in transcriptional regulation that may influence cell proliferation, differentiation and death. These epigenetic modifications are controlled by complex enzymatic machinery that includes specific histone methylases and demethylases. Deregulation of this machinery could alter chromatin configuration and disrupt normal transcriptional programs, both of which are features of cancer cells. Indeed, genomic alterations of MLL, NSD1, CREBBP (CBP) and WHSC1 (MMSET), all encoding proteins involved in post-translational histone modification, have been implicated in acute leukemias and myeloma (http://www. sanger.ac.uk/genetics/CGP/Census/).
As part of systematic mutational screens of the coding genome (http://www.sanger.ac.uk/genetics/CGP/Studies/), we investigated the role of mutations of the histone methylation machinery in human cancer. A combination of PCR-based resequencing of coding exons for point mutations, SNP array hybridization for copy number changes and multiplex exonic PCR identified 39 inactivating mutations in 1,390 cancer samples ( Table 1 and Supplementary Tables 1 and 2 online) in UTX, located on Xp11.2 and encoding a histone H3 lysine 27 (H3K27) demethylase [2] [3] [4] .
Inactivating mutations in UTX included 16 homozygous (in females) or hemizygous (in males) large deletions, 9 nonsense mutations, 12 small frame-shifting insertion/deletions and 2 consensus splice site mutations that lead to aberrant splicing and premature termination codons ( Table 1) . All large homozygous and hemizygous deletions were confirmed by PCR ( Supplementary Fig. 1 and Supplementary Table 3 online). Nine were contained within the genomic footprint of UTX, indicating that UTX is the target of the homozygous deletion cluster (Supplementary Fig. 1 ).
Matching constitutional DNA was available from 12 cancers with inactivating mutations. Eleven proved to be somatic upon analysis (seven in primary cancers and four in cancer cell lines). The exception was a nonsense mutation in a renal cancer found to be a germline allele, suggesting that UTX mutations may contribute to genetic susceptibility in rare instances. The ratio of truncating to nontruncating somatic single-base substitutions (Supplementary Table 4 online) observed in UTX was 1:2 compared to 1:17 expected by chance, indicating selection for inactivating variants. To assess the likely provenance of the 28 inactivating variants found in samples for which no constitutional DNA was available, we sequenced all UTX coding exons in constitutional DNA from 400 male controls. No truncating variants were identified. Furthermore, 411 normal DNAs were evaluated on Affymetrix SNP6.0 arrays for copy number changes, and no instances of homozygous or hemizygous deletions were detected. It is therefore likely that most were somatically acquired.
Protein blot analysis showed no detectable protein in any of 24 cancers with homozygous inactivating mutations ( Fig. 1a and data not shown). In addition to the alterations described above, which are clearly predicted to inactivate the protein, two overlapping but nonidentical deletions within intron 2 of UTX were detected in two cancer cell lines. One line expressed no detectable UTX transcript or protein (RPMI-8226), whereas the other (U-266) expressed UTX transcript and protein. By contrast, 14 cancers of diverse tissue origins with wild-type UTX sequence all showed readily detectable protein expression ( Fig. 1a and data not shown). The pattern of inactivating mutations is consistent with UTX acting as a tumor suppressor gene.
UTX mutations were found in multiple cancer types. The highest prevalence, 10% (6/58), was observed in multiple myeloma. Of note, activation of WHSC1 (MMSET), which encodes a protein shown to have methylase activity toward H3K27 (ref. 5 ) and other histone residues 6 , has also been implicated in multiple myeloma. Notably, the UTX null multiple myeloma samples reported here are all negative for the MMSET-activating t(4;14) translocation [6] [7] [8] , suggesting potential mutual exclusion of mutations. Inactivating UTX mutations were also detected in 8% (6/77) of esophageal squamous cell carcinomas and 1.4% (6/419) of renal cell carcinomas. For these three cancer types, the total number of mutations reflects both an initial screening series followed by the identification of additional mutations in a larger follow-up series. As primary tumors were not analyzed for homozygous or hemizygous deletions, the prevalence of inactivating mutations is likely an underestimate. Other cancer types with inactivating mutations included myeloid leukemias, breast and colorectal cancers and glioblastoma.
UTX is one of a limited number of genes on the X chromosome that escapes X inactivation in females 9 . Therefore, in contrast to the X-linked tumor suppressor gene WTX, which is subject to X inactivation 10 , biallelic mutations of UTX in females may be necessary to contribute to oncogenesis. There was a trend among the 16 cancer cell lines with inactivating mutations derived from cancers in females to lose the other UTX allele, with 11/16 (65%) as compared to 111/262 (42%) UTX wild-type cancers showing loss of heterozygosity (P ¼ 0.039). In further support of biallelic UTX inactivation, examination of cDNA and protein from the remaining six lines with heterozygous truncating mutations revealed one, PF-382, with loss of the wild-type transcript and no UTX protein expression and one, SNU-C2B, with both wild-type and mutant transcripts present but no UTX protein.
The remaining four cell lines ( Table 1 ) expressed both mutant and wild-type transcripts, had detectable UTX protein expression and may represent passenger events.
Males have only a single copy of UTX. However, there is a paralog on the Y chromosome, UTY, which shows 83% amino-acid identity 9 . We investigated whether UTY may be functioning as the second tumor suppressor gene allele to UTX in males. Genomic loss of UTY in male cancer lines with inactivating UTX mutations (13/16, 81%) was significantly more frequent than UTY loss in UTX wild-type cancers (153/307, 49%) (P ¼ 0.0142). In addition, a focal UTY deletion was found in a single myeloma line, U-266. Overall, the data support an allelic role of UTY for UTX, although in vivo studies indicate that purified UTY does not fully recapitulate the equivalent histone demethylase activity of UTX 3, 11 . Taking the data from female and male cancers together, there is support for a two-hit model of UTX-UTY inactivation, with P ¼ 0.0016 for loss of either UTX or UTY in samples with an inactivating UTX mutation versus wild type.
UTX is one of two recently identified histone H3 lysine 27 demethylases [2] [3] [4] . Methylation at lysine 27 is highly correlated with genomic silencing and repression of transcription 1 . UTX is also a component of the mixed-lineage-leukemia (MLL)2/3 complexes that promote histone H3 lysine 4 (H3K4) methylation 4, 12 , a mark of open and actively transcribed chromatin 1 . A concerted mechanism of transcriptional control involving cycles of H3K27 and H3K4 methylation linked via UTX has been proposed 2, 4 . This transcriptional control would likely be subverted by the UTX inactivating mutations reported here. Following from this, we evaluated the functional impact of UTX mutations. We observed no correlation between global H3K27me3 and H3K4me3 levels measured via protein blot in UTX null lines compared to UTX wild-type samples (data not shown). To further investigate potential mechanisms of involvement in oncogenesis, wild-type UTX was expressed in two UTX null cell lines (KYSE-180 and KYSE-450) and a UTX wild-type line (NCI-H1299). Reexpression of UTX resulted in significant increases in cell doubling time compared to empty vector controls in the two null lines but had no discernable effect in the wild-type line, even though expression was increased over endogenous levels (Fig. 1b) . We then used microarray analysis to investigate whether UTX reintroduction induced gene expression changes. Both null lines showed greater changes in gene expression (KYSE-180, n ¼ 327 genes; KYS3-450, n ¼ 241 genes; FDR o 0.05) upon UTX re-expression compared to the NCI-H1299 UTX wild-type line (n ¼ 46 genes, FDR o 0.05; Supplementary Table 5 online). The sets of differentially expressed genes from the transfectants were analyzed for possible enrichment of genes associated with the H3K27 methylating polycomb complex and/or H3K27me3 and H3K4me3 marks 13, 14 (Supplementary Methods online). There was no enrichment for any of these gene sets in the UTX wild-type control line (P 4 0.1 for all three datasets). However, significant enrichment (P o 0.001) was found for polycomb genes in both UTX null lines transfected with wild-type UTX. Of note, in both lines, there was enrichment for H3K27me3 marked genes (KYSE180, P o 0.0001; KYSE450, P ¼ 0.065) but not H3K4me3 (KYSE180, P ¼ 0.7; KYSE450, P ¼ 0.3). ChIP-PCR of SOX21 and PCDH19, two genes showing significant expression changes in the transfected UTX null lines, demonstrated a significant decrease (P o 0.05) in H3K27me3 levels upon UTX reintroduction (Fig. 1c) , suggesting that the expression changes were a direct effect of reconstituted UTX demethylase activity. These data indicate that mutational inactivation of UTX is likely to be acting, at least in part, through transcriptional control mechanisms.
Taken together, these results provide strong evidence for UTX as the first mutated histone demethylase gene that is associated with human cancer, indicating that genetic mechanisms may underpin a substantial component of epigenetic deregulation in cancers.
Note: Supplementary information is available on the Nature Genetics website. Table 3 . ACTB and APRT are negative controls for H3K27me3 marks; SFRP4 is a positive antibody control for H3K27me3. Controls are all taken from Schlesinger et al. 15 . White bars, empty vector control; gray bars, UTX reintroduction. Asterisks in a and b indicate common nonspecific band.
